Company Profiles

driven by the PitchBook Platform

Abide Therapeutics

Description

Developer of an innovative therapeutic platform designed to target serine hydrolases. The company's therapeutic platform exploits the power of chemoproteomics to mine the serine hydrolase superfamily for novel drug targets, enabling health care providers to harness the therapeutic potential of serine hydrolases to yield drugs for treatment of a broad range of diseases in areas of unmet medical need.

PRIVATE

Status

11-50

Employees

Series A

Latest Deal Type

$6.6M

Latest Deal Amount

$8.8M

Total Amount Raised

2

Investors

Description

Developer of an innovative therapeutic platform designed to target serine hydrolases. The company's therapeutic platform exploits the power of chemoproteomics to mine the serine hydrolase superfamily for novel drug targets, enabling health care providers to harness the therapeutic potential of serine hydrolases to yield drugs for treatment of a broad range of diseases in areas of unmet medical need.

Website:

www.abidetx.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Therapeutic Devices

Primary Office

10835 Road to the Cure Suite 250 San Diego, CA 92121United States +1 (858) 427-2590
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Abide Therapeutics's full profile, request a free trial.

Abide Therapeutics Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Abide Therapeutics Investors (2)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Cardinal PartnersVenture CapitalMinority000 0000000 0000
Cure Alzheimer's FundAngel (individual)000 0000000 0000
Cardinal Partners Venture Capital
Cure Alzheimer's Fund Angel (individual)

Abide Therapeutics Executive Team (12)

NameTitleBoard
Seat
Contact
Info
Cheri Grice Ph.DVice President, Chemistry
Iain Fraser Ph.DVice President, Early Clinical Development
Chan BealsChief Medical Officer
Stan BlackburnChief Financial Officer
Alan Ezekowitz Ph.DCo-Founder, Board Member, President & Chief Executive Officer
Cheri Grice Ph.D Vice President, Chemistry
Iain Fraser Ph.D Vice President, Early Clinical Development
Chan Beals Chief Medical Officer
Stan Blackburn Chief Financial Officer
Alan Ezekowitz Ph.D Co-Founder, Board Member, President & Chief Executive Officer

Abide Therapeutics Board Members (6)

NameRepresentingRoleSinceContact
Info
Alan Ezekowitz Ph.DAbide TherapeuticsCo-Founder, Board Member, President & Chief Executive Officer000 0000
Benjamin Cravatt Ph.DAbide TherapeuticsCo-Founder, Scientific Advisory Board & Board Member000 0000
John ClarkeCardinal PartnersCo-Founder & Managing General Partner000 0000
Nancy ThornberrySelfBoard Member000 0000
Paul Schimmel Ph.DAbide TherapeuticsCo-Founder & Board Member000 0000
Alan Ezekowitz Ph.D Co-Founder, Board Member, President & Chief Executive Officer Abide Therapeutics
Benjamin Cravatt Ph.D Co-Founder, Scientific Advisory Board & Board Member Abide Therapeutics
John Clarke Co-Founder & Managing General Partner Cardinal Partners
Nancy Thornberry Board Member Self
Paul Schimmel Ph.D Co-Founder & Board Member Abide Therapeutics
Request full access to PitchBook